Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Not reaching lowest symp.. 60% Improvement Relative Risk Not reaching lowest.. (b) 50% Time to first occurrence o.. 43% Time to release from qua.. 27% primary c19hcq.org Amaravadi et al. HCQ for COVID-19 RCT EARLY TREATMENT Is early treatment with HCQ beneficial for COVID-19? Double-blind RCT 29 patients in the USA Improved recovery with HCQ (not stat. sig., p=0.13) Amaravadi et al., medRxiv, doi:10.1101/2021.02.22.21252228 Favors HCQ Favors control
Hydroxychloroquine for SARS-CoV-2 positive patients quarantined at home: The first interim analysis of a remotely conducted randomized clinical trial
Amaravadi et al., medRxiv, doi:10.1101/2021.02.22.21252228 (Preprint)
Amaravadi et al., Hydroxychloroquine for SARS-CoV-2 positive patients quarantined at home: The first interim analysis of a.., medRxiv, doi:10.1101/2021.02.22.21252228 (Preprint)
Feb 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Tiny early-terminated 34 patient RCT for outpatient treatment showing faster recovery with treatment (not statistically significant). All patients recovered (3 control patients recovered after crossover to the treatment arm) - as per protocol mid-recovery results have priority. There was no mortality and only one hospitalization on day 0 before treatment. There were no severe adverse events.
risk of not reaching lowest symptom score at day 7 mid-recovery, 60.0% lower, RR 0.40, p = 0.13, treatment 3 of 15 (20.0%), control 6 of 12 (50.0%), NNT 3.3.
risk of not reaching lowest symptom score at day 5 mid-recovery, 50.0% lower, RR 0.50, p = 0.13, treatment 5 of 15 (33.3%), control 8 of 12 (66.7%), NNT 3.0.
relative time to first occurrence of lowest symptom score, 42.9% lower, relative time 0.57, p = 0.38, treatment median 4.0 IQR 13.0 n=15, control median 7.0 IQR 10.0 n=12.
relative time to release from quarantine, 27.3% lower, relative time 0.73, p = 0.46, treatment median 8.0 IQR 15.0 n=16, control median 11.0 IQR 14.0 n=13, primary outcome.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Amaravadi et al., 26 Feb 2021, Double Blind Randomized Controlled Trial, USA, preprint, 20 authors, dosage 400mg bid days 1-14.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2021.02.22.21252228; this version posted February 26, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Hydroxychloroquine for SARS-CoV-2 positive patients quarantined at home: The first interim analysis of a remotely conducted randomized clinical trial Ravi K. Amaravadi, MD1*, Lydia Giles1; Mary Carberry1, Matthew C. Hyman, MD PhD2; Ian Frank, MD3; Sunita D. Nasta, MD1; Jennifer Walsh1; E. Paul Wileyto, PhD5; Phyllis Gimotty, PhD5; Michael Milone, MD PhD6; Edith M. Teng, BA7, Niraj J. Vyas, MBS7, Steve Balian, MD7, Jonathan A. Kolansky, BA7, Nabil M. Abdulhay, BS7, Shaun K. McGovern, BS BSN7, Sarah Gamblin, BA7, Olivia Doran, BS7, Paul L. Callahan, BA7, Benjamin S. Abella MD MPhil7 Affiliations: 1- Abramson Cancer Center and Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania 2- Division of Cardiology, Department of Medicine University of Pennsylvania 3- Division of Infectious Disease, Department of Medicine University of Pennsylvania 4- Department of Microbiology, University of Pennsylvania 5- Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania 6- Department of Pathology, University of Pennsylvania 7-Department of Emergency Medicine, University of Pennsylvania *Corresponding author: Ravi Amaravadi, MD Division of Hematology-Oncology 8 BRB - Room 852 Philadelphia, PA 19104 Office: 215-769-5159 Email: ravi.amaravadi@pennmedicine.upenn.edu Conflict of Interest Statement: The authors report no relevant conflicts of interest Abstract word count:262 Manuscript word count:3497 Key words: COVID-19, hydroxychloroquine Running Title: Trial of hydroxychloroquine for outpatient treatment of COVID-19 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2021.02.22.21252228; this version posted February 26, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Amaravadi et al ‐ Trial of hydroxychloroquine for outpatient treatment of COVID‐19 2 ABSTRACT Background Older patients are at risk of increased morbidity and mortality from COVID-19 disease due to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). There are few effective treatments for outpatients with COVID-19. Objective To evaluate the efficacy of hydroxychloroquine to reduce time in quarantine for symptomatic ≥40 years-old COVID-19 patients. Design A randomized, double-blind, placebo-controlled clinical trial. Setting Outpatients with polymerase chain reaction confirmed COVID-19 at a University of Pennsylvania affiliated testing center between April 15, 2020 and, July 14, 2020. Participants Out of 5511 SARS-CoV-2 positive patients, 1072 met initial eligibility criteria for telephonebased recruitment, but only 34 subjects were able to be randomized. Interventions Hydroxychloroquine 400 mg per twice daily (n=17) or matching placebo (n=17), taken orally for up to 14 days. Measurements The primary outcome was the time to release from quarantine...
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit